Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial

Tobias Forster 1,2,3, Clara Köhler 1, Melissa Dorn 1, Matthias Felix Häfner 1,2,3, Nathalie Arians 1,2,3, Laila König 1,2,3, Semi Ben Harrabi 1,2,3, Ingmar Schlampp 1,2,3, Eva Meixner 1,2,3, Vanessa Heinrich 4, Nicola Weidner 4, Michael Golatta 5, André Hennigs 5, Jörg Heil 5, Holger Hof 6, David Krug 1,2,3,7, Jürgen Debus 1,2,3,8,9,10 and Juliane Hörner-Rieber 1,2,3,8,*

1 Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany; tobias.forster@med.uni-heidelberg.de (T.F.); koehler@stud.uni-heidelberg.de (C.K.); melissadorn97@gmail.com (M.D.); matthias.haefner@med.uni-heidelberg.de (M.F.H.); nathalie.arians@med.uni-heidelberg.de (N.A.); laila.koenig@med.uni-heidelberg.de (L.K.); semi.harrabi@med.uni-heidelberg.de (S.B.H.); ingmar.schlampp@med.uni-heidelberg.de (I.S.); eva.meixner@med.uni-heidelberg.de (E.M.); david.krug@uksh.de (D.K.); juergen.debus@med.uni-heidelberg.de (J.D.)
2 Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany
3 National Center for Tumor Diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany
4 Department of Radiation Oncology, Eberhard-Karls-University Tuebingen, 72070 Tuebingen, Germany; vanessa.heinrich@med.tuebingen.de (V.H.); n.weidner@med.tuebingen.de (N.W.)
5 Department of Gynecology and Obstetrics, University of Heidelberg, 69115 Heidelberg, Germany; michael.golatta@med.uni-heidelberg.de (M.G.); andre.hennigs@med.uni-heidelberg.de (A.H.); joerg.heil@med.uni-heidelberg.de (J.H.)
6 Strahlentherapie Rhein-Pfalz, 67433 Neustadt, Germany; hof@strahlentherapie-neustadt.de
7 Department of Radiation Oncology, University Hospital Schleswig Holstein, 24105 Kiel, Germany
8 Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
9 Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany
10 German Cancer Consortium (DKTK), Partner Site Heidelberg, Heidelberg University Hospital, 69120 Heidelberg, Germany
* Correspondence: juliane.hoerner-rieger@med.uni-heidelberg.de; Tel.: +49-6221-56-8201; Fax: +49-6221-5353

Simple Summary: To validate the BCCT.core software, the present analysis compares the esthetics assessment by the software in relation to patients’ and physicians’ rating in breast cancer patients after surgery and adjuvant radiotherapy. Agreement rates of the different assessments and their correlation with breast asymmetry indices were evaluated. The assessments of the software and the physicians were significantly correlated with all asymmetry indices, while for patients’ self-assessment, this correlation was first seen after 2 years. Only a slight agreement between the BCCT.core software and the physicians’ or patients’ assessment was seen, while a moderate and substantial agreement was detected between the physicians’ and the patients’ assessments. The BCCT.core software is a reliable tool to measure asymmetries, but may not sufficiently evaluate the esthetic outcome as perceived by patients. It may be more appropriate for a long-term follow-up, when symmetry seems to increase in importance.

Abstract: The present analysis compares the esthetics assessment by the BCCT.core software in relation to patients’ and physicians’ ratings, based on the IMRT-MC2 trial. Within this trial, breast cancer patients received breast-conserving surgery (BCS) and adjuvant radiotherapy. At the baseline, 6 weeks, and 2 years after radiotherapy, photos of the breasts were assessed by the software and patients’ and physicians’ assessments were performed. Agreement rates of the assessments and their correlation with breast asymmetry indices were evaluated. The assessments of the software
Cancers 2022, 14, 3010

and the physicians were significantly correlated with asymmetry indices. Before and 6 weeks after radiotherapy, the patients’ self-assessment was only correlated with the lower breast contour (LBC) and upward nipple retraction (UNR), while after 2 years, there was also a correlation with other indices. Only a slight agreement between the BCCT.core software and the physicians’ or patients’ assessment was seen, while a moderate and substantial agreement was detected between the physicians’ and the patients’ assessment after 6 weeks and 2 years, respectively. The BCCT.core software is a reliable tool to measure asymmetries, but may not sufficiently evaluate the esthetic outcome as perceived by patients. It may be more appropriate for a long-term follow-up, when symmetry appears to increase in importance.

Keywords: breast cancer; adjuvant whole-breast radiotherapy; esthetic assessment; BCCT.core software; cosmesis

1. Introduction

Due to the early detection of breast cancer, increasing rates of breast conservation, and improvements in long-term survival, the esthetic outcome of breast-conserving therapy is coming more and more into focus for both caregivers and caretakers. In terms of radiation oncology, the use of boost irradiation is a major determinant of esthetic outcome [1–3]. Thus, for the evaluation of new radiotherapy techniques, the esthetic outcome is undoubtedly a highly important outcome parameter. Different methods are reported in the literature to measure the esthetic outcome: subjective approaches, such as patients’ self-assessment and third-party assessment performed by a single physician or a panel of physicians, and objective techniques, primarily measuring symmetry [4–6]. Subjective panel evaluation and self-assessment continue to be the most commonly used methods for evaluating esthetic outcome [7]. To improve the reproducibility and comparability of subjective esthetics assessments, the standardized four-point Harvard Scale was introduced by Harris et al., and broadly used by the research community [8]. Nevertheless, in breast cancer therapy, the reproducibility of subjective assessments of esthetic outcome still remains limited [9,10]. Furthermore, a subjective evaluation performed by a panel of experts is an expensive, difficult, and time-consuming procedure [10]. Therefore, a reliable, highly reproducible, and simple method for esthetic assessment is urgently needed for future research approaches. The BCCT.core (Breast Cancer Conservative Treatment. Cosmetic Result) software is a cost-free, semi-automated, and easy-to-use tool, which provides a highly reliable and reproducible assessment of esthetic outcome [11–14]. In previous studies, the validity of the BCCT.core software was tested by comparing the results of the program to a subjective panel assessment [11,12,15]. Furthermore, the agreement of the software results with the patient perspective was tested in comparison to the BCTOS (Breast Conservative Treatment Outcome Scale) Aesthetic Status [13]. However, the number of cases tested in these trials were rather small, consisting of 30 to 128 patients. In the present study, the esthetic outcome data of the prospective, two-armed, randomized phase III IMRT-MC2 trial were used for an in-depth validation of the BCCT.core software with a larger number of cases. For this purpose, the software results were analyzed in comparison to physicians’ assessments and patients’ self-assessment of the esthetic outcome.

2. Results

The IMRT-MC2 trial randomized 502 patients to the control arm (3-D-CRT-seqB) and the experimental arm (IMRT-SIB) in a 1:1 ratio. For a total of 472 patients, 433 patients, and 378 patients, a complete assessment of esthetic outcome was available at the baseline, at 6 weeks, and 2 years after radiotherapy, respectively. These patients were eligible for the present analysis. For the three time points, the characteristics of patients, tumors, and treatments are summarized in Table 1. At the baseline, the median age of the participants...
was 55 years. Most patients presented with T1 stage disease (74%), and were staged pN0 (80%). In most cases, the tumor was located in the upper outer quadrant of the breast (61%).

Table 1. Patient, tumor, and treatment characteristics.

| Characteristic                  | Baseline | 6 Weeks | 2 Years |
|---------------------------------|----------|---------|---------|
|                                 | No.  | %     | No.  | %     | No.  | %     |
| **Patient Characteristics**     |       |       |       |       |       |       |
| Age at diagnosis                |       |       |       |       |       |       |
| Median (years)                  | 55.0  | 54.0  | 56.0  |       |       |       |
| Range (years)                   | 27–81 | 30–78 | 30–78 |       |       |       |
| **Tumor Characteristics**       |       |       |       |       |       |       |
| Side                            |       |       |       |       |       |       |
| Right breast                    | 208  | 44.1  | 186  | 42.9  | 170  | 45.0  |
| Left breast                     | 264  | 55.9  | 247  | 57.1  | 208  | 55.0  |
| Quadrant                        |       |       |       |       |       |       |
| Lower inner                     | 51   | 10.8  | 44   | 10.2  | 18   | 4.8   |
| Lower outer                     | 72   | 15.3  | 65   | 15.0  | 57   | 15.1  |
| Upper inner                     | 115  | 24.4  | 100  | 23.1  | 92   | 24.3  |
| Upper outer                     | 289  | 61.2  | 187  | 43.2  | 179  | 47.4  |
| Multiple Quadrants              | 39   | 8.3   | 37   | 8.5   | 32   | 8.5   |
| Pathologic stage                |       |       |       |       |       |       |
| ≤pT1                            | 347  | 73.5  | 320  | 73.9  | 278  | 73.5  |
| pT2                             | 117  | 24.8  | 106  | 24.5  | 95   | 25.2  |
| pT3                             | 5    | 1.1   | 4    | 0.9   | 3    | 0.8   |
| pT4                             | 3    | 0.6   | 3    | 0.7   | 2    | 0.5   |
| pN0                             | 377  | 79.9  | 343  | 79.2  | 302  | 79.9  |
| pN1                             | 76   | 16.1  | 72   | 16.6  | 60   | 15.9  |
| pN2                             | 16   | 3.4   | 15   | 3.5   | 13   | 3.4   |
| pN3                             | 3    | 0.6   | 3    | 0.7   | 3    | 0.8   |
| Treatment Characteristics       |       |       |       |       |       |       |
| Axillary dissection             |       |       |       |       |       |       |
| Yes                             | 101  | 21.4  | 97   | 22.4  | 79   | 20.9  |
| No                              | 371  | 78.6  | 336  | 77.6  | 299  | 79.1  |
| Nodal irradiation               |       |       |       |       |       |       |
| Yes                             | 67   | 14.2  | 62   | 14.3  | 55   | 14.6  |
| No                              | 405  | 85.8  | 371  | 85.7  | 323  | 85.4  |
| Chemotherapy                    |       |       |       |       |       |       |
| None                            | 266  | 56.4  | 243  | 56.1  | 213  | 56.3  |
| Neoadjuvant only                | 76   | 16.1  | 69   | 15.9  | 63   | 16.7  |
| Adjuvant only                   | 127  | 26.9  | 118  | 27.3  | 100  | 26.5  |
| Neoadjuvant and adjuvant        | 3    | 0.6   | 3    | 0.7   | 2    | 0.5   |
| Anthracycline-based chemotherapy|       |       |       |       |       |       |
| Yes                             | 135  | 28.6  | 118  | 27.3  | 105  | 27.8  |
| No                              | 337  | 71.4  | 315  | 72.7  | 237  | 72.2  |
Table 1. Cont.

| Characteristic                  | Baseline No. | Baseline % | 6 Weeks No. | 6 Weeks % | 2 Years No. | 2 Years % |
|---------------------------------|--------------|------------|-------------|-----------|-------------|-----------|
| **Taxane-based chemotherapy**   |              |            |             |           |             |           |
| Yes                             | 159          | 33.7       | 139         | 32.1      | 132         | 34.9      |
| No                              | 313          | 66.3       | 294         | 67.9      | 246         | 65.1      |
| **Trastuzumab-based therapy**   |              |            |             |           |             |           |
| Yes                             | 25           | 5.3        | 21          | 4.8       | 15          | 4.0       |
| No                              | 447          | 94.7       | 412         | 95.2      | 363         | 96.0      |
| **Endocrine therapy**           |              |            |             |           |             |           |
| Yes                             | 330          | 69.9       | 298         | 68.8      | 265         | 70.1      |
| No                              | 142          | 30.1       | 135         | 31.2      | 113         | 29.9      |
| **Radiotherapy**                |              |            |             |           |             |           |
| IMRT-SIB                        | 235          | 49.8       | 213         | 49.2      | 192         | 50.8      |
| 3D-CRT-seqB                     | 237          | 50.2       | 220         | 50.8      | 186         | 49.2      |
| Total                           | 472          | 100.0      | 433         | 100.0     | 378         | 100.0     |

Abbreviations: No.: number; IMRT-SIB: conventional fractionated intensity-modulated radiotherapy with simultaneously integrated boost; 3D-CRT-seqB: 3D-conformal radiotherapy with sequential boost; SIB: simultaneously integrated boost.

2.1. Correlation between Breast Asymmetry Indices and Overall Esthetic Scores

The correlations between different breast asymmetry indices and overall esthetic outcomes of the BCCT.core software, as well as between breast asymmetry indices and patients’ or physicians’ assessment scores, at the baseline, 6 weeks, and two years after radiotherapy are shown in Table 2.

For the overall esthetic score of the BCCT.core software, a significant correlation was seen with all asymmetry indices at all time points. The highest Pearson correlation score was detected for the lower breast contour (LBC), which indicates the difference between the level of the inferior breast contours (Pearson coefficient: 0.669, 0.554, and 0.688 for the three time points, respectively; \( p < 0.001 \)).

Table 2. Correlations between breast asymmetry indices and overall esthetic outcomes of BCCT.core, and between breast asymmetry indices and patients’ or physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy (four-point scale: excellent–good–fair–poor).

| BCCT.Core | Patients’ Self-Assessment | Physicians’ Assessment |
|-----------|---------------------------|------------------------|
|  | Pearson | \( p \)-Value | Pearson | \( p \)-Value | Pearson | \( p \)-Value |
| baseline (\( n = 472 \)) | | | | | | |
| pBRA | 0.447 | \(<0.001\) | 0.051 | 0.266 | 0.172 | \(<0.001\) |
| LBC | 0.669 | \(<0.001\) | 0.143 | 0.002 | 0.211 | \(<0.001\) |
| UNR | 0.535 | \(<0.001\) | 0.098 | 0.032 | 0.200 | \(<0.001\) |
| BCE | 0.239 | \(<0.001\) | 0.051 | 0.265 | 0.116 | 0.012 |
| BCD | 0.593 | \(<0.001\) | 0.070 | 0.126 | 0.201 | \(<0.001\) |
| BAD | 0.415 | \(<0.001\) | 0.026 | 0.579 | 0.125 | 0.007 |
| BOD | 0.489 | \(<0.001\) | 0.070 | 0.127 | 0.159 | 0.001 |
Table 2. Cont.

|                        | BCCT.Core Pearson | 6 Weeks after Radiotherapy (n = 433) | Patients’ Self-Assessment Pearson | Physicians’ Assessment Pearson |
|------------------------|------------------|--------------------------------------|-----------------------------------|-------------------------------|
|                        | p-Value          |                                      | p-Value                           | p-Value                       |
| pBRA                   | 0.321            | <0.001                               | 0.092                             | 0.055                         | 0.180                         | <0.001                        |
| LBC                    | 0.554            | <0.001                               | 0.135                             | 0.005                         | 0.190                         | <0.001                        |
| UNR                    | 0.391            | <0.001                               | 0.108                             | 0.025                         | 0.205                         | <0.001                        |
| BCE                    | 0.134            | 0.005                                | 0.117                             | 0.015                         | 0.196                         | <0.001                        |
| BCD                    | 0.505            | <0.001                               | 0.082                             | 0.088                         | 0.141                         | 0.003                         |
| BAD                    | 0.394            | <0.001                               | 0.091                             | 0.060                         | 0.157                         | 0.001                         |
| BOD                    | 0.504            | <0.001                               | 0.108                             | 0.024                         | 0.157                         | 0.001                         |

|                        | BCCT.Core Pearson | 2 Years after Radiotherapy (n = 378) | Patients’ Self-Assessment Pearson | Physicians’ Assessment Pearson |
|------------------------|------------------|--------------------------------------|-----------------------------------|-------------------------------|
|                        | p-Value          |                                      | p-Value                           | p-Value                       |
| pBRA                   | 0.357            | <0.001                               | 0.203                             | <0.001                        | 0.293                         | <0.001                        |
| LBC                    | 0.688            | <0.001                               | 0.246                             | <0.001                        | 0.283                         | <0.001                        |
| UNR                    | 0.454            | <0.001                               | 0.201                             | <0.001                        | 0.285                         | <0.001                        |
| BCE                    | 0.147            | 0.004                                | 0.154                             | 0.003                         | 0.219                         | <0.001                        |
| BCD                    | 0.621            | <0.001                               | 0.301                             | <0.001                        | 0.313                         | <0.001                        |
| BAD                    | 0.507            | <0.001                               | 0.261                             | <0.001                        | 0.284                         | <0.001                        |
| BOD                    | 0.535            | <0.001                               | 0.246                             | <0.001                        | 0.317                         | <0.001                        |

A Pearson correlation score was used to determine the correlation between breast asymmetry indices and overall cosmetic outcomes of BCCT.core, as well as between breast asymmetry indices and patients’ or physicians’ assessment scores at the baseline, 6 weeks, and 2 years after radiotherapy. A two-sided significance test was used to compute the statistical significance. Statistically significant p-values (p ≤ 0.05) are presented in bold.

Abbreviations: n: number of valid assessments; pBRA: breast retraction assessment; LBC: lower breast contour; UNR: upward nipple retraction; BCE: breast compliance evaluation; BCD: breast contour difference; BAD: breast area difference; BOD: breast overlap difference; Bold: The bold is for highlighting significant values.

At the baseline, 6 weeks, and two years after radiotherapy, the overall physicians’ assessment of esthetic outcome also significantly correlated with all breast asymmetry indices. For physicians’ assessments of esthetics, the Pearson correlation coefficients were lower than the correlation coefficients seen for the cosmetic score of the BCCT.core software, indicating a stronger correlation of asymmetry indices with the score of the BCCT.core software.

Only for LBC and upward nipple retraction (UNR) was a significant correlation with the patients’ self-assessment of esthetics seen at all time points. However, two years after radiotherapy, all asymmetry indices were significantly correlated with the patients’ self-assessment.

When the four-point scale of esthetics was dichotomized into a two-point scale, no correlation between breast asymmetry indices and patients’ self-assessment of esthetics was seen for the baseline and 6 weeks after radiotherapy time points. Otherwise, no differences were seen between the analysis of the four-point and the two-point scale (Table 3).
Table 3. Correlations between breast asymmetry indices and overall esthetic outcomes of BCCT.core, and between breast asymmetry indices and patients’ or physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy (two-point scale: excellent/good–fair/poor).

| BCCT.Core | Patients’ Self-Assessment | Physicians’ Assessment |
|-----------|---------------------------|------------------------|
| Pearson   |  $p$-Value                | Pearson | $p$-Value | Pearson | $p$-Value |
| pBRA      | 0.441 | <0.001 | −0.039 | 0.399 | 0.177 | <0.001 |
| LBC       | 0.590 | <0.001 | 0.053 | 0.248 | 0.227 | <0.001 |
| UNR       | 0.524 | <0.001 | 0.015 | 0.740 | 0.226 | <0.001 |
| BCE       | 0.243 | <0.001 | 0.005 | 0.912 | 0.145 | 0.002 |
| BCD       | 0.495 | <0.001 | 0.004 | 0.937 | 0.214 | <0.001 |
| BAD       | 0.328 | <0.001 | −0.017 | 0.708 | 0.128 | 0.005 |
| BOD       | 0.433 | <0.001 | 0.010 | 0.820 | 0.169 | <0.001 |

6 Weeks after Radiotherapy ($n = 433$)

| pBRA      | 0.321 | <0.001 | −0.007 | 0.890 | 0.152 | 0.002 |
| LBC       | 0.573 | <0.001 | 0.054 | 0.262 | 0.138 | 0.004 |
| UNR       | 0.420 | <0.001 | 0.032 | 0.504 | 0.209 | <0.001 |
| BCE       | 0.168 | <0.001 | 0.082 | 0.090 | 0.230 | <0.001 |
| BCD       | 0.499 | <0.001 | 0.026 | 0.588 | 0.128 | 0.008 |
| BAD       | 0.405 | <0.001 | 0.003 | 0.955 | 0.109 | 0.024 |
| BOD       | 0.517 | <0.001 | 0.030 | 0.536 | 0.040 | 0.403 |

2 Years after Radiotherapy ($n = 378$)

| pBRA      | 0.373 | <0.001 | 0.176 | 0.001 | 0.260 | <0.001 |
| LBC       | 0.652 | <0.001 | 0.232 | <0.001 | 0.235 | <0.001 |
| UNR       | 0.457 | <0.001 | 0.173 | 0.001 | 0.258 | <0.001 |
| BCE       | 0.210 | <0.001 | 0.085 | 0.101 | 0.184 | <0.001 |
| BCD       | 0.568 | <0.001 | 0.252 | <0.001 | 0.245 | <0.001 |
| BAD       | 0.457 | <0.001 | 0.220 | <0.001 | 0.208 | <0.001 |
| BOD       | 0.530 | <0.001 | 0.184 | <0.001 | 0.238 | <0.001 |

A Pearson correlation score was used to determine correlation between breast asymmetry indices and overall cosmetic outcomes of BCCT.core, as well as between breast asymmetry indices and patients’ or physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy. A two-sided significance test was used to compute the statistical significance. Statistically significant $p$-values ($a \leq 0.05$) are presented in bold. Abbreviations: N: number of valid assessments; pBRA: breast retraction assessment; LBC: lower breast contour; UNR: upward nipple retraction; BCE: breast compliance evaluation; BCD: breast contour difference; BAD: breast area difference; BOD: breast overlap difference; Bold: The bold is for highlighting significant values.

### 2.2. Agreement of BCCT.Core Software Results with Patients’ and Physicians’ Assessment Scores

The agreement of the BCCT.core software results for esthetics with patients’ or physicians’ assessment scores, as well as the agreement of patients’ assessment scores with physicians’ assessment scores, are depicted in Table 4 for the baseline, 6 weeks, and two years after radiotherapy.
Table 4. Agreement of BCCT.core software results with patients’ or physicians’ assessment scores, and agreement of patients’ assessment scores with physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy (four-point scale: excellent–good–fair–poor).

|                          | a   | k   | p-Value (k) | wk  | p-Value (wk) |
|--------------------------|-----|-----|-------------|-----|--------------|
| **Baseline**             |     |     |             |     |              |
| BCCT.core vs. patients’ assessment | 225/472 | 0.088 | **0.019**   | 0.109 | **0.003**   |
| BCCT.core vs. physicians’ assessment | 167/472 | -0.029 | 0.178       | 0.027 | 0.173        |
| patients’ assessment vs. physicians’ assessment | 205/472 | 0.052 | **0.024**   | 0.100 | <0.001      |
| **6 Weeks after Radiotherapy** |     |     |             |     |              |
| BCCT.core vs. patients’ assessment | 146/433 | -0.002 | 0.952       | 0.024 | 0.321        |
| BCCT.core vs. physicians’ assessment | 157/433 | 0.051 | 0.060       | 0.084 | **0.001**   |
| patients’ assessment vs. physicians’ assessment | 313/433 | 0.516 | <0.001      | 0.572 | <0.001      |
| **2 Years after Radiotherapy** |     |     |             |     |              |
| BCCT.core vs. patients’ assessment | 149/378 | 0.052 | 0.138       | 0.111 | **0.002**   |
| BCCT.core vs. physicians’ assessment | 151/378 | 0.069 | **0.050**   | 0.138 | <0.001      |
| patients’ assessment vs. physicians’ assessment | 274/378 | 0.543 | <0.001      | 0.625 | <0.001      |

Cohen’s Kappa statistic was used to determine agreement of the BCCT.core software results with patients’ or physicians’ assessment scores, as well as agreement of patients’ assessment scores with physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy. Rates of total agreement, Kappa coefficients, and weighted Kappa coefficients with their respective p-values are indicated. Statistically significant p-values (a ≤ 0.05) are presented in bold. Abbreviations: a: rate of total agreement; k: Kappa coefficient; wk: weighted Kappa coefficient; p-value (k): p-value of the Kappa coefficient; p-value (wk): p-value of the weighted Kappa coefficient; vs.: versus; Bold: The bold is for highlighting significant values.

At the baseline, there was only a slight agreement between the BCCT.core software results and patients’ self-assessment scores (weighted Kappa (wk) = 0.109; p = 0.003), as well as between patients’ and physicians’ assessment scores (wk = 0.100; p < 0.001). In the time points of 6 weeks and 2 years after radiotherapy, only a slight agreement was seen for the BCCT.core esthetic results and physicians’ assessment scores (wk = 0.084; p = 0.001, wk = 0.138; p < 0.001, respectively). For the correlation of BCCT.core results and patients’ self-assessment two years after therapy, there was also only slight agreement (wk = 0.111; p = 0.002). On the other hand, moderate and even substantial agreement was seen for patients’ and physicians’ assessment scores both 6 weeks (wk = 0.572; p < 0.001) and two years (wk = 0.625; p < 0.001) after radiotherapy, respectively.

In general, an increase in agreement was seen over time: With increasing time since therapy, the agreement also increased, with the highest agreement rates presented after two years, and the lowest values at the baseline. After dichotomizing the four-point scale of esthetics, there was no substantial change in the results of the analysis. However, the level of agreement was generally lower (Table 5).
Table 5. Agreement of the BCCT.core software results with patients’ or physicians’ assessment scores, and agreement of patients’ assessment scores with physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy (two-point scale: excellent/good–fair/poor).

|                                | a     | k     | p-Value (k) | wk    | p-Value (wk) |
|--------------------------------|-------|-------|-------------|-------|--------------|
| **Baseline**                   |       |       |             |       |              |
| BCCT.core vs. patients’ assessment | 397/472 | -0.036 | 0.433       | -0.036 | 0.433        |
| BCCT.core vs. physicians’ assessment | 393/472 | 0.144  | 0.001       | 0.144  | 0.001        |
| patients’ assessment vs. physicians’ assessment | 392/472 | 0.127  | 0.004       | 0.127  | 0.004        |
| **6 Weeks after Radiotherapy** |       |       |             |       |              |
| BCCT.core vs. patients’ assessment | 304/433 | -0.005 | 0.883       | -0.005 | 0.883        |
| BCCT.core vs. physicians’ assessment | 309/433 | 0.072  | 0.080       | 0.072  | 0.080        |
| patients’ assessment vs. physicians’ assessment | 388/433 | 0.344  | <0.001      | 0.344  | <0.001        |
| **2 Years after Radiotherapy** |       |       |             |       |              |
| BCCT.core vs. patients’ assessment | 301/378 | 0.213  | <0.001      | 0.213  | <0.001        |
| BCCT.core vs. physicians’ assessment | 301/378 | 0.244  | <0.001      | 0.244  | <0.001        |
| patients’ assessment vs. physicians’ assessment | 336/378 | 0.532  | <0.001      | 0.532  | <0.001        |

Cohen’s Kappa statistic was used to determine agreement of the BCCT.core software results with patients’ or physicians’ assessment scores, as well as agreement of patients’ assessment scores with physicians’ assessment scores, at the baseline, 6 weeks, and 2 years after radiotherapy. The rates of total agreement, Kappa coefficients, and weighted Kappa coefficients with their respective p-values are indicated. Statistically significant p-values (a ≤ 0.05) are presented in bold. Abbreviations: a: rate of total agreement; k: Kappa coefficient; wk: weighted Kappa coefficient; p-value (k): p-value of the Kappa coefficient; p-value (wk): p-value of the weighted Kappa coefficient; vs.: versus; Bold: The bold is for highlighting significant values.

3. Discussion

As the overall esthetic score of the BCCT.core software is primarily based on asymmetry measurements, a strong correlation with breast asymmetry indices was detected in the present analysis at all time points. This effect was expected, and was strongest for LBC, which is in line with results of Yu et al., also reporting the highest Pearson correlation score for this asymmetry index [16]. Physicians’ assessment of esthetics also significantly correlated with breast asymmetry indices. Although the effect was not as strong as for the BCCT.core software, it demonstrates that physicians’ assessments also appear to be predominantly influenced by asymmetry. This is in line with results of Lyngholm et al., who analyzed late morbidity, esthetic outcome, and body image of 214 patients from the Danish Breast Cancer Cooperative Group after breast-conserving therapy. This study demonstrated that breast asymmetry measured by BRA was the only factor that correlated with physicians’ assessments of esthetic outcome [17].

For patients’ self-assessment, a significant correlation with asymmetry indices at the baseline and 6 weeks after radiotherapy mark was only seen for LBC and UNR in the present study. Other asymmetry scores, such as the pBRA, significantly correlated with patients’ assessments only after two years. Assumingly, for patients immediately after surgery and radiotherapy factors, other than asymmetry, such as scars, fibrosis, hyperpigmentation, or even pain, may have a stronger influence on esthetic self-assessment. Then, as time passes,
the symmetry of the breast may rise again in importance. This effect may also explain the stabilization of the esthetic outcome 3 years after therapy, as it is found in most previous studies [18–22]. As an uneven lower breast contour and nipple position, measured with LBC and UNR, are the most eye-catching parameters of asymmetry, it may be reasonable that a correlation of these factors and patients’ esthetics assessments was detected earlier after treatment. Only a weak correlation of patients’ esthetics rating with asymmetry indices, as seen in the present work, was also observed by Yu et al.; at a median follow-up of two years after breast-conserving therapy, the authors evaluated the esthetic outcome rated by the 51 patients themselves, and did not find any significant correlation with breast asymmetry measurements [16]. Some authors argue that assessment of esthetics with a four-point scale is less appropriate for patients, and that these global rating categories, when used by patients themselves, may only reflect perceived differences between treated and untreated breasts [23,24]. In an analysis of Patterson et al., 94% of patients rated the esthetic outcome after breast-conserving therapy as good or excellent, although 50% of patients reported relevant differences between the treated and untreated breast [25]. However, rating by physicians may be considered to be fairly subjective as well.

The present analysis indicates a stronger agreement for physicians’ assessments of esthetic outcome (moderate and substantial agreement 6 weeks and 2 years after therapy, respectively) than for the assessment with the BCCT.core software (only slight agreement). This is in line with similar agreement rates detected in previous studies; in an analysis of Heil et al.’s study, which included 128 patients, a slight to fair agreement was seen between the BCCT.core results and patients’ assessments of esthetics, tested with the BCTOS Aesthetic Status questionnaire [13]. A study of Yu et al., including 51 patients, also demonstrated only a slight agreement between BCCT.core software results and patients’ self-assessment 2 years after whole-breast radiotherapy [16].

In the current analysis, the observed effect of a stronger agreement with physicians’ assessments than with the BCCT.core results may be due to a more holistic and less asymmetry-based evaluation of the breast by the physicians, taking into account other relevant factors, such as scars and pigmentation. Representative examples of agreement and disagreement of the software results with patients’ and physicians’ assessment scores are depicted in Figure 1. However, two years after radiotherapy, an increase in agreement rates, as compared to patients’ self-assessment, was detected for both the physicians’ assessment and the assessment by the software. This observed increase in agreement levels for the software results with patients’ self-assessment may be due to a rising importance of symmetry for the patients with time. Therefore, the BCCT.core software appears to be a better measurement method for long-term follow-up of the esthetic outcome, rather than evaluating the esthetic results immediately after therapy.

When comparing our findings to the results of the previous studies of Haloua et al., Cardoso et al. and Heil et al., we could not confirm similar high rates of agreement of physicians’ assessment and BCCT.core software results (reported Kappa: 0.27 to 0.64) [11,12,15,26]. This may partly be explained by the fact that, in those studies, the physicians’ rating was performed by a panel, rather than by a single physician, as was the case in the present prospective phase III trial. For the current analysis, physicians’ assessment was performed by live observation and palpation, as recommended by previous authors [27], to detect outcome variables such as edema, fibrosis, and telangiectasia more easily. In this setting, a panel evaluation was not feasible. Although intra-rater agreement in third-party assessment of the esthetic outcome is described to be substantial in the literature [28], a suboptimal intra-rater agreement may have weakened the present analysis. Unfortunately, intra-rater agreement was not tested in the present work. Moreover, the rating physician was one of the treating radiation oncologists. This may have influenced the physicians’ assessment towards a more positive esthetic outcome.

A strength of the present study, in addition to the large number of patients assessed, is the use and comparison of all three methods of esthetics assessment (subjective, objective, and self-assessment) as recommended in the literature [7]. In particular, the results of
patients’ self-assessment provide a highly relevant reference for the present analysis, as well as for future studies. Furthermore, in the current analysis, the application of the standardized four-point scale of Harris et al., in combination with photographic examples [8,18], as recommended by Vrieling et al. [24], makes it easy to compare our results to those of other authors.

Figure 1. Esthetic results assessed with BCCT.core. Representative examples of excellent outcome, good outcome, fair outcome, and poor outcome, with agreement of the BCCT.core software results with patients’ and physicians’ assessment scores shown together with the definition of the Harvard Scale (A), as well as representative examples of disagreement (B).
According to our analysis, the BCCT.core software is an excellent tool for reliably measuring asymmetry, which appears to be a strong influencing factor for physicians’ assessment of esthetics. However, in the first weeks after breast-conserving therapy, patients’ self-assessment appears to depend less on asymmetry indices. Patients’ self-assessment is certainly the most relevant method to measure the esthetic outcome, even if this is not objective. Nevertheless, the reliability of patients’ assessment and its use for validation purposes is controversially discussed in the literature, as subjective assessments may not necessarily agree with the objective scores, and have very low reproducibility values [11,13,24,29]. In the literature, the application of both a qualitative and a quantitative method of measuring the esthetic outcome is recommended, especially when skin changes such as scars are relevant, since a single assessment that covers all of this complexity will probably never exist [18,24].

4. Patients and Methods

4.1. Description of Analyzed Patients

The present investigation was based on the esthetic outcome of participants of the IMRT-MC2 prospective, two-armed, multi-center, randomized phase III trial at the baseline of, as well as 6 weeks and 2 years after, whole-breast irradiation (WBI). The multicenter IMRT-MC2 trial recruited from March 2011 until August 2015 at the University Hospital Tübingen and the University Hospital Heidelberg. The University of Heidelberg ethics committee (S-041/2009) and the Federal Office of Radiation Protection (BfS) (Z5-22461/2-2009-18) (ClinicalTrial.gov Protocol ID is NCT01322854) approved the protocol. The German Aerospace Center (DLR)/Federal Ministry of Education and Research (BMBF) of Germany (01ZP0504) funded the IMRT-MC2 trial. All patients received breast-conserving surgery, followed by adjuvant WBI with boost irradiation to the former tumor bed. Adjuvant WBI was delivered either with IMRT (helical tomotherapy or step-and-shoot technique) to a total dose of 50.4 Gy in 1.8 Gy single fractions with a simultaneous integrated boost (SIB) to the tumor bed to a total dose of 64.4 Gy in 28 fractions of 2.3 Gy (IMRT-SIB), or with 3D-conformal radiotherapy (3D-CRT) to the whole breast to a total dose of 50.4 Gy and 1.8 Gy per fraction in 28 fractions, followed by a sequential boost (seqB) to a total dose of 66.4 Gy at 2 Gy dose per fraction in 8 fractions (3D-CRT-seqB) [30,31]. Detailed information about target volume delineation, dose prescription, dose constraints, and treatment planning have been published previously [30,31].

All participants of the IMRT-MC2 trial with a complete assessment of esthetic outcome were included in the present analysis. All patients of the present analysis gave their written informed consent to participate in the study, and were characterized by the following criteria: all patients had to have an indication for adjuvant WBI with boost irradiation to the former tumor bed. Patients needed to be aged ≥ 18 years and < 70 years, or aged ≥ 70 years with one of the following risk factors: multifocal disease, tumor stage ≥ T2, extensive intraductal component, lymphangiosis and resection margins ≤ 3 mm, Karnofsky Performance Score > 70%, no metastatic disease (M0), no previous radiotherapy of the same breast or thorax, no other malignancies in the previous 5 years, no pregnancy [30].

4.2. Software Analysis of Esthetic Outcome Using BCCT.Core Software

Each patient of the present analysis received a standardized photographic documentation of the breasts shortly before radiotherapy (baseline), as well as 6 weeks and 2 years after irradiation. Using the following same procedure for every woman, frontal photographs of both breasts excluding the face were taken: standing position with hanging arms, equal standardized exposure to light, equal distance of 2.5 m from camera to patient, equal background in blue color. The sternal notch, as well as a point 25 cm below, were marked with red dots to allow for the correction of the magnification of the photographs. For each patient and for every single time point, these photographs were analyzed using the BCCT.core software (Breast Research Group, Porto, Portugal) to calculate breast asymmetry indices and an overall score of the esthetic result. This software was developed to summarize all
objective symmetry measurements ever described in one single tool [5–7,9,15,18,32]. After importing a standardized photograph into the software, predetermined points are designated by the user, and the breast contour is semi-automatically delineated (Figure 2). In a following step, the BCCT.core software calculates different asymmetry indices, including breast volume, skin color, and scars. Finally, an algorithm combines these indices in an overall esthetic result, displayed on a four-point scale (1 = excellent, 2 = good, 3 = fair, 4 = poor). All measurements and calculations were performed by the same investigator (TF) who was blinded regarding timepoint and randomization.

Figure 2. Screenshot of BCCT.core software. The sternal notch, a point 25 cm below, and both nipples are marked. After the user has adjusted the red dots to the most medial and lateral point of the breast outline, the BCCT.core software is able to auto adjust the breast outline and to calculate several asymmetry indices, as well as an overall score (four-point scale: excellent–good–fair–poor).

4.3. Patients’ and Physicians’ Assessment of Esthetic Outcome

Shortly before radiotherapy (baseline), as well as 6 weeks and 2 years after irradiation, the esthetic outcome was assessed by both the treating physician and the patient using the Radiation Therapy Oncology Group/Harvard Scale, comparing the treated breast to the untreated one. The esthetic outcome was scored according to a four-point scale: excellent (no visible treatment sequelae at first sight), good (minimal changes), fair (the treated breast is different but not seriously distorted), or poor (the treated breast is seriously distorted) [8]. The rating physicians were all radiation oncologists, and had at least 2 years’ experience in the field.

4.4. Statistical Methods

For the agreement analyses of patients’ and physicians’ subjective scoring and the objective software scoring of esthetic outcome, absolute agreement rates (a), Kappa (k), and weighted Kappa (wk) statistics were used [33,34]. The agreement analysis was performed separately for the 3 different times of assessment: baseline (before radiotherapy), 6 weeks, and 2 years after radiotherapy. To interpret the Kappa and weighted Kappa coefficients, we used the definition recommended by Seigel et al.: ≤0 indicates poor agreement, 0.01–0.20 slight agreement, 0.21–0.40 fair agreement, 0.41–0.60 moderate agreement, 0.61–0.80 substantial agreement, 0.81–0.99 almost perfect agreement, and 1.00 perfect agreement [35]. Using absolute agreement rates (a), Kappa (k), and weighted Kappa (wk), we tested agreement of the esthetic scores (four-point scale) of the BCCT.core software and
the patients’ subjective scoring, of the BCCT.core software and the physicians’ subjective scoring, and of the patients’ and the physicians’ subjective scoring. In a second step, the four-point scale of the patients’, physicians’, and software assessment was dichotomized into “excellent/good” and “fair/poor” esthetic outcomes, and the statistical analysis was repeated for this two-point scale.

For the correlation analyses of different breast asymmetry indices and subjective patients’, subjective physicians’, and objective software scores for overall esthetic outcome (four-point scale), a Pearson correlation coefficient was used [36]. The correlation analysis was performed separately for the three different times of assessment, as mentioned above. Again, the four-point scale of the esthetic outcome was dichotomized into “excellent/good” and “fair/poor”, and the correlation analysis was repeated for the two-point scale.

Data analyses were performed with the IBM Statistical Package for Social Sciences software, version 19 (SPSS Inc., Chicago, IL), to calculate Kappa, weighted Kappa, the Pearson coefficient, and $p$-values. A two-sided significance test was used to compute the statistical significance. The level of statistical significance was set at $p \leq 0.05$.

5. Conclusions

The presented data demonstrate that an assessment by the BCCT.core software alone may not be sufficient to evaluate the esthetic outcome in the way that it is perceived by the patients. The BCCT.core software is a good and reliable tool to measure objective asymmetries, but it should be complemented by physicians’ assessment and patients’ self-assessment to take the subjective perception of esthetics into account. The BCCT.core software may be more appropriate for measuring the esthetic outcome in a long-term follow-up, when symmetry appears to become more important for patients.

Author Contributions: T.F. and J.H.-R. carried out the data analysis and interpretation. M.D. helped with data collection. T.F. drafted the manuscript. T.F., J.H.-R. and J.D. conceived the study concept. T.F., M.F.H., N.A., L.K., S.B.H., I.S., V.H., N.W., E.M., J.H., M.G., D.K., A.H., H.H. and J.H.-R. helped with patient recruitment, radiotherapy planning, and treatment. J.H.-R. and C.K. assisted in drafting the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The IMRT-MC2-trial was funded by the German Aerospace Center (DLR)/Federal Ministry of Education and Research (BMBF) (01ZP0504). The funding source had no role in the study design, collection, analysis, and interpretation of data. We acknowledge financial support by the Medical Faculty of Heidelberg University within the physician scientist program.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics committee of Heidelberg University (S-041/2009).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data presented in this article are available on request to the editor or the reviewers. Open Access publishing is supported.

Conflicts of Interest: JHR received speaker fees and travel reimbursement from ViewRay Inc., as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside of the submitted work. JHR received grants from IntraOP Medical and Varian Medical Systems outside of the submitted work. DK received honoraria from Merck Sharp and Dohme and Pfizer, as well as research funding from Merck KGaA outside of the submitted work. JD received grants from CRI – The Clinical Research Institute GmbH, View Ray Inc., Accuray International, Accuray Incorporated, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Merck Serono GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co., PTW-Freiburg Pzychlau GmbH, and Nanobiotix A.A., as well as IntraOP Medical outside of the submitted work. All other authors declare that they have no conflict of interest.
Abbreviations

3D-CRT 3D-conformal radiotherapy
3D-CRT-seqB 3D-conformal radiotherapy with sequential boost
a rate of total agreement
BAD breast area difference
BCCT.core Breast Cancer Conservative Treatment. Cosmetic Result
BCD breast contour difference
BCE breast compliance evaluation
BCS breast-conserving surgery
BCTOS Breast Conservative Treatment Outcome Scale
BOD breast overlap difference
BRA/pBRA breast retraction assessment
IMRT intensity-modulated radiotherapy
IMRT-SIB conventional fractionated intensity-modulated radiotherapy with simultaneously integrated boost.
k Kappa coefficient
LBC lower breast contour
SD standard deviation
seqB sequential boost
SIB simultaneously integrated boost
UNR upward nipple retraction
WBI whole-breast irradiation
wk weighted Kappa coefficient

References

1. Harsolia, A.; Kestin, L.; Grills, I.; Wallace, M.; Jolly, S.; Jones, C.; Lala, M.; Martinez, A.; Schell, S.; Vicini, F.A. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 2007, 68, 1375–1380. [CrossRef] [PubMed]

2. van Dongen, J.A.; Bartelink, H.; Fentiman, I.S.; Lerut, T.; Mignolet, F.; Olthuis, G.; van der Schueren, E.; Sylvester, R.; Winter, J.; van Zijl, K. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. *J. Natl. Cancer Inst. Monogr.* 1992, 11, 15–18.

3. Vrieling, C.; Collette, L.; Fourquet, A.; Hoogenraad, W.J.; Horiot, J.C.; Jager, J.J.; Poortmans, P.M.; Struikmans, H.; Van der Hulst, M.; et al. The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 1999, 45, 677–685. [CrossRef]

4. Al-Ghazal, S.K.; Blamey, R.W. Cosmetic assessment of breast-conserving surgery for primary breast cancer. *Breast* 1999, 8, 162–168. [CrossRef]

5. Pezner, R.D.; Patterson, M.P.; Hill, L.R.; Vora, N.; Desai, K.R.; Archambeau, J.O.; Lipsett, J.A. Breast retraction assessment: An objective evaluation of cosmetic results of patients treated conservatively for breast cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 1985, 11, 575–578. [CrossRef]

6. Van Limbergen, E.; van der Schueren, E.; Van Tongelen, K. Cosmetic evaluation of breast conserving treatment for mammary cancer. 1. Proposal of a quantitative scoring system. *Radiother. Oncol.* 1989, 16, 159–167. [CrossRef]

7. Cardoso, M.J.; Cardoso, J.S.; Oliveira, H.P.; Gouveia, P. The breast cancer conservative treatment. Cosmetic results—BCCT.core—Software for objective assessment of esthetic outcome in breast cancer conservative treatment: A narrative review. *Comput. Methods Programs Biomed.* 2016, 126, 154–159. [CrossRef]

8. Harris, J.R.; Levene, M.B.; Svensson, G.; Hellman, S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. *Int. J. Radiat. Oncol. Biol. Phys.* 1979, 5, 257–261. [CrossRef]

9. Cardoso, M.J.; Cardoso, J.S.; Oliveiro, H.P.; Gouveia, P. Comparing two objective methods for the aesthetic evaluation of breast cancer conservative treatment. *Breast Cancer Res. Treat.* 2009, 116, 149–152. [CrossRef] [PubMed]
13. Heil, J.; Dahlkamp, J.; Golatta, M.; Rom, J.; Domschke, C.; Rauch, G.; Cardoso, M.J.; Sohn, C. Aesthetics in breast conserving therapy: Do objectively measured results match patients’ evaluations? *Ann. Surg. Oncol.* **2011**, *18*, 134–138. [CrossRef] [PubMed]

14. Cardoso, M.J.; Cardoso, J.; Santos, A.C.; Vrieling, C.; Christie, D.; Liljegren, G.; Azeevedo, I.; Johansen, J.; Rosa, J.; Amaral, N.; et al. Factors determining aesthetic outcome after breast cancer conservative treatment. *Breast J.* **2007**, *13*, 140–146. [CrossRef]

15. Cardoso, M.J.; Cardoso, J.; Amaral, N.; Azeevedo, I.; Barreau, L.; Bernardo, M.; Christie, D.; Costa, S.; Fitzal, F.; Fougou, J.L.; et al. Turning subjective into objective: The BCCT.core software for evaluation of cosmetic results in breast cancer conservative treatment. *Breast* **2007**, *16*, 456–461. [CrossRef]

16. Yu, T.; Eom, K.Y.; Jang, N.Y.; Kim, K.S.; Koo, T.R.; Kwon, J.; Kim, B.H.; Kang, E.; Kim, S.W.; Kim, J.S.; et al. Objective Measurement of Cosmetic Outcomes of Breast Conserving Therapy Using BCCT.core. *Cancer Res. Treat.* **2016**, *48*, 491–498. [CrossRef]

17. Lyngholm, C.D.; Christiansen, P.M.; Damsgaard, T.E.; Overgaard, J. Long-term follow-up of late morbidity, cosmetic outcome and body image after breast conserving therapy. A study from the Danish Breast Cancer Cooperative Group (DBCG). *Acta Oncol.* **2013**, *52*, 259–269. [CrossRef]

18. Van Limbergen, E.; Rijnders, A.; van der Schueren, E.; Lerut, T.; Christiaens, R. Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. *Radiother. Oncol.* **1989**, *16*, 253–267. [CrossRef]

19. de la Rochefordiere, A.; Abner, A.L.; Silver, B.; Vicini, F.; Recht, A.; Harris, J.R. Are cosmetic results following conservative surgery and radiation therapy for early breast cancer dependent on technique? *Int. J. Radiat. Oncol. Biol. Phys.* **1992**, *23*, 925–931. [CrossRef]

20. Markiewicz, D.A.; Schultz, D.J.; Haas, J.A.; Harris, E.E.; Fox, K.R.; Glick, J.H.; Solin, L.J. The effects of sequence and type of chemoradiotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* **1996**, *35*, 661–668. [CrossRef]

21. Gray, J.R.; McCormick, B.; Cox, L.; Yahalom, J. Primary breast irradiation in large-breasted or heavy women: Analysis of cosmetic outcome. *Int. J. Radiat. Oncol. Biol. Phys.* **1991**, *21*, 347–354. [CrossRef]

22. Rose, M.A.; Olivotto, I.; Cady, B.; Koufman, C.; Osteen, R.; Silver, B.; Recht, A.; Harris, J.R. Conservative surgery and radiation therapy for early breast cancer. Long-term cosmetic results. *Arch. Surg.* **1989**, *124*, 153–157. [CrossRef] [PubMed]

23. Sneeuw, K.C.; Aaronson, N.K.; Yarnold, J.R.; Broderick, M.; Regan, J.; Ross, G.; Goddard, A. Cosmetic and functional outcomes of conservative breast conserving treatment for early breast cancer. 1. Comparison of patients’ ratings, observers’ ratings, and objective assessments. *Radiother. Oncol.* **1992**, *25*, 153–159. [CrossRef]

24. Vrieling, C.; Collette, L.; Bartelink, E.; Borger, J.H.; Brenninkmeyer, S.J.; Hoving, J.; Poortmans, P.M.; Struikmans, H.; Tiefenbacher, U.; Wenz, F.; et al. Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. *Int. J. Radiat. Oncol. Biol. Phys.* **1999**, *45*, 667–676. [CrossRef]

25. Patterson, M.P.; Pezner, R.D.; Hill, L.R.; Vora, N.L.; Desai, K.R.; Lipsett, J.A. Patient self-evaluation of cosmetic outcome of breast-preserving cancer treatment. *Int. J. Radiat. Oncol. Biol. Phys.* **1985**, *11*, 1849–1852. [CrossRef]

26. Haloua, M.H.; Krekel, N.M.; Jacobs, G.J.; Zonderhuis, B.; Bouman, M.B.; Buncamper, M.E.; Niessen, F.B.; Winters, H.A.; ter Wee, C.; Meijer, S.; et al. Cosmetic Outcome Assessment following Breast-Conserving Therapy: A Comparison between BCCT.core Software and Panel Evaluation. *Int. J. Breast Cancer* **2014**, *2014*, 716860. [CrossRef]

27. Christie, D.; O’Brien, M.Y.; Christie, J.A.; Kron, T.; Ferguson, S.A.; Hamilton, C.S.; Denham, J.W. A comparison of methods of cosmetic assessment in breast conservation treatment. *Breast* **1996**, *5*, 358–367. [CrossRef]

28. Fortin, A.J.; Cheang, M.; Latosinsky, S. Cosmetic outcomes following breast conservation therapy: In search of a reliable scale. *Breast Cancer Res. Treat.* **2006**, *100*, 65–70. [CrossRef]

29. Al-Ghazal, S.K.; Fallowfield, L.; Blamey, R.W. Patient evaluation of cosmetic outcome after conserving surgery for treatment of primary breast cancer. *Eur. J. Surg. Oncol.* **1999**, *25*, 344–346. [CrossRef]

30. Askoxylakis, V.; Jensen, A.D.; Hafner, M.F.; Fetzner, L.; Sterzing, F.; Heil, J.; Sohn, C.; Husing, J.; Tiefenbacher, U.; Wenz, F.; et al. Simultaneous integrated boost for adjuvant treatment of breast cancer—intensity modulated vs. conventional radiotherapy: The IMRT-MC2 trial. *BMC Cancer* **2011**, *11*, 249. [CrossRef]

31. Horner-Rieber, J.; Forster, T.; Hommertgen, A.; Haefner, M.F.; Arians, N.; König, L.; Harrabi, S.B.; Schlampp, I.; Weykamp, F.; Lischalk, J.W.; et al. Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). *Int. J. Radiat. Oncol. Biol. Phys.* **2020**, *109*, 1311–1324. [CrossRef] [PubMed]

32. Cardoso, J.S.; Pinto da Costa, J.F.; Cardoso, M.J. Modelling ordinal relations with SVMs: An application to objective aesthetic evaluation of breast cancer conservative treatment. *Neural Netw.* **2005**, *18*, 808–817. [CrossRef] [PubMed]

33. Fleiss, J.L.; Cohen, J. The Equivalence of weighted kappa and the Intraclass Correlation coefficient as measures of reliability. *Educ. Psychol. Meas.* **1973**, *33*, 613–619. [CrossRef]

34. Cicchetti, D.; Allison, T. A new procedure for assessing reliability of scoring eeg sleep recordings. *Am. J. EEG Technol.* **1971**, *11*, 101–109. [CrossRef]
35. Seigel, D.C.; Podgo, M.J.; Remaley, N.A. Acceptable values of kappa for comparison of two groups. *Am. J. Epidemiol.* 1992, 135, 571–578. [CrossRef]

36. SPSS Tutorials: Pearson Correlation. Available online: https://libguides.library.kent.edu/SPSS/PearsonCorr (accessed on 24 November 2021).